Lifecore Biomedical, Inc. LFCR Temporary Equity, Accretion to Redemption Value, Adjustment
Temporary Equity, Accretion to Redemption Value, Adjustment at other companies
Other financials
Where this comes from
Reported directly by Lifecore Biomedical, Inc. in its filing.
Tagged under the XBRL concept us-gaap:TemporaryEquityAccretionToRedemptionValueAdjustment.
The official record: Lifecore Biomedical, Inc.’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →
Ask your AI about Lifecore Biomedical, Inc.'s temporary equity, accretion to redemption value, adjustment.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Lifecore Biomedical, Inc.'s temporary equity, accretion to redemption value, adjustment?
- Lifecore Biomedical, Inc. (LFCR) reported temporary equity, accretion to redemption value, adjustment of $47K in Q1 2026.
- How has Lifecore Biomedical, Inc.'s temporary equity, accretion to redemption value, adjustment changed year-over-year?
- Lifecore Biomedical, Inc.'s temporary equity, accretion to redemption value, adjustment decreased by 2.1% year-over-year, from $48K to $47K.
- What does temporary equity, accretion to redemption value, adjustment mean?
- This represents the periodic increase in the carrying amount of temporary equity instruments to reach their mandatory or probable redemption value. It effectively treats the accretion as a charge against earnings available to common shareholders, similar to a dividend. This metric is critical for evaluating the true cost of capital for instruments that do not qualify as permanent equity.